Advertisement

Use of New Vitamin D Analogs in Chronic Kidney Disease

  • Riccardo Floreani
  • Mario CozzolinoEmail author
Chapter

Abstract

Vitamin D is a common treatment against secondary hyperparathyroidism in renal patients. However, the rationale for the prescription of vitamin D sterols in chronic kidney disease (CKD) is rapidly increasing due to the coexistence of growing expectancies close to unsatisfactory evidences, such as the lack of randomized controlled trials (RCTs) proving the superiority of any vitamin D sterol against placebo on patient-centered outcomes, the scanty clinical data on head-to-head comparisons between the multiple vitamin D sterols currently available, the absence of RCTs confirming the crescent expectations on nutritional vitamin D pleiotropic effects even in CKD patients and the promising effects of vitamin D receptors activators (VDRA) against proteinuria and myocardial hypertrophy in diabetic CKD cohorts. The present chapter arguments these issues focusing on the opened questions that nephrologists should consider dealing with the prescription and the choice of a VDRA.

Keywords

VDRA Alfacalcidol Doxercalciferol Paricalcitol Cinacalcet Secondary hyperparathyroidism Albuminuria Left ventricular hypertrophy Left atrial dimension Bone histology Bone mineral density Kidney transplantation 

References

  1. 1.
    Hamdy NA, Kanis JA, Beneton MN, Brown CB, Juttmann JR, Jordans JG, Josse S, Meyrier A, Lins RL, Fairey IT. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ. 1995;310(6976):358–63.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Rix M, Eskildsen P, Olgaard K. Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. Nephrol Dial Transplant. 2004;19(4):870–6.CrossRefPubMedGoogle Scholar
  3. 3.
    El-Husseini AA, El-Agroudy AE, El-Sayed M, Sobh MA, Ghoneim MA. A prospective randomized study for the treatment of bone loss with vitamin d during kidney transplantation in children and adolescents. Am J Transplant. 2004;4(12):2052–7.CrossRefPubMedGoogle Scholar
  4. 4.
    El-Husseini AA, El-Agroudy AE, El-Sayed MF, Sobh MA, Ghoneim MA. Treatment of osteopenia and osteoporosis in renal transplant children and adolescents. Pediatr Transplant. 2004;8(4):357–61.CrossRefPubMedGoogle Scholar
  5. 5.
    De Sévaux RG, Hoitsma AJ, Corstens FH, Wetzels JF. Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study. J Am Soc Nephrol. 2002;13(6):1608–14.CrossRefPubMedGoogle Scholar
  6. 6.
    Trabulus S, Altiparmak MR, Apaydin S, Serdengecti K, Sariyar M. Treatment of renal transplant recipients with low bone mineral density: a randomized prospective trial of alendronate, alfacalcidol, and alendronate combined with alfacalcidol. Transplant Proc. 2008;40(1):160–6.CrossRefPubMedGoogle Scholar
  7. 7.
    El-Reshaid K, El-Reshaid W, Sugathan T, Al-Mohannadi S, Sivanandan R. Comparison of the efficacy of two injectable forms of vitamin D3 and oral one-alpha in treatment of secondary hyperparathyroidism in patients on maintenance hemodialysis. Am J Nephrol. 1997;17(6):505–10.CrossRefPubMedGoogle Scholar
  8. 8.
    Moe S, Wazny LD, Martin JE. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial. Can J Clin Pharmacol. 2008;15(1):e36–43. Epub 2008 Jan 9.PubMedGoogle Scholar
  9. 9.
    Kiattisunthorn K, Wutyam K, Indranoi A, Vasuvattakul S. Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients. Nephrology (Carlton). 2011;16(3):277–84.CrossRefGoogle Scholar
  10. 10.
    Hansen D, Rasmussen K, Danielsen H, Meyer-Hofmann H, Bacevicius E, Lauridsen TG, Madsen JK, Tougaard BG, Marckmann P, Thye-Roenn P, Nielsen JE, Kreiner S, Brandi L. No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial. Kidney Int. 2011;80(8):841–50.CrossRefPubMedGoogle Scholar
  11. 11.
    Coburn JW, Maung HM, Elangovan L, Germain MJ, Lindberg JS, Sprague SM, Williams ME, Bishop CW. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis. 2004;43(5):877–90.CrossRefPubMedGoogle Scholar
  12. 12.
    Frazão JM, Elangovan L, Maung HM, Chesney RW, Acchiardo SR, Bower JD, Kelley BJ, Rodriguez HJ, Norris KC, Robertson JA, Levine BS, Goodman WG, Gentile D, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW. Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism. Am J Kidney Dis. 2000;36(3):550–61.CrossRefPubMedGoogle Scholar
  13. 13.
    Maung HM, Elangovan L, Frazão JM, Bower JD, Kelley BJ, Acchiardo SR, Rodriguez HJ, Norris KC, Sigala JF, Rutkowski M, Robertson JA, Goodman WG, Levine BS, Chesney RW, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis. 2001;37(3):532–43.CrossRefPubMedGoogle Scholar
  14. 14.
    Zisman AL, Ghantous W, Schinleber P, Roberts L, Sprague SM. Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol. Am J Nephrol. 2005;25(6):591–5.CrossRefPubMedGoogle Scholar
  15. 15.
    Fadem SZ, Al-Saghir F, Zollner G, Swan S. Converting hemodialysis patients from intravenous paricalcitol to intravenous doxercalciferol – a dose equivalency and titration study. Clin Nephrol. 2008;70(4):319–24.CrossRefPubMedGoogle Scholar
  16. 16.
    Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, Fadem S, Levine B, Williams L, Andress DL, Sprague SM. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis. 2006;47:263–76.CrossRefPubMedGoogle Scholar
  17. 17.
    Coyne DW, Goldberg S, Faber M, Ghossein C, Sprague SM. A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3–4 CKD. Clin J Am Soc Nephrol. 2014;9(9):1620–6.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Komenda P, Rigatto C, Tangri N. Estimated glomerular filtration rate and albuminuria: diagnosis, staging, and prognosis. Curr Opin Nephrol Hypertens. 2014;23(3):251–7.CrossRefPubMedGoogle Scholar
  19. 19.
    De Zeeuw D, Lambers Heerspink HJ, Gansevoort RT, Bakker SJL. How to improve renal outcome in diabetes and hypertension – the importance of early screening for and treatment of microalbuminuria. Eur Nephrol. 2009;3:13–5.Google Scholar
  20. 20.
    Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol. 2007;18(5):1540–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, Williams L, Batlle D. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005;68(6):2823–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Liu LJ, Lv JC, Shi SF, Chen YQ, Zhang H, Wang HY. Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis. 2012;59(1):67–74.CrossRefPubMedGoogle Scholar
  23. 23.
    De Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 2010;376(9752):1543–51.CrossRefPubMedGoogle Scholar
  24. 24.
    Larsen T, Mose FH, Bech JN, Pedersen EB. Effect of paricalcitol on renin and albuminuria in non-diabetic stage III–IV chronic kidney disease: a randomized placebo-controlled trial. BMC Nephrol. 2013;14:163.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Bae S, Yalamarti B, Ke Q, Choudhury S, Yu H, Karumanchi SA, Kroeger P, Thadhani R, Kang PM. Preventing progression of cardiac hypertrophy and development of heart failure by paricalcitol therapy in rats. Cardiovasc Res. 2011;91(4):632–9.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Pilz S, Tomaschitz A, Drechsler C, de Boer RA. Vitamin D deficiency and heart disease. Kidney Int Suppl. 2011;1:111–5.CrossRefGoogle Scholar
  27. 27.
    Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS, Rigor DL, Stillman I, Tamez H, Kroeger PE, Wu-Wong RR, Karumanchi SA, Thadhani R, Kang PM. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A. 2007;104(43):16810–5.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, Solomon SD. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA. 2012;307(7):674–84.CrossRefPubMedGoogle Scholar
  29. 29.
    Wang AY, Fang F, Chan J, Wen YY, Qing S, Chan IH, Lo G, Lai KN, Lo WK, Lam CW, Yu CM. Effect of paricalcitol on left ventricular mass and function in CKD – the OPERA trial. J Am Soc Nephrol. 2014;25(1):175–86.CrossRefPubMedGoogle Scholar
  30. 30.
    Tamez H, Zoccali C, Packham D, Wenger J, Bhan I, Appelbaum E, Pritchett Y, Chang Y, Agarwal R, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Singh B, Zehnder D, Pachika A, Manning WJ, Shah A, Solomon SD, Thadhani R. Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J. 2012;164(6):902–9.e2.CrossRefPubMedGoogle Scholar
  31. 31.
    Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol. 2002;90(12):1284–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Patel RK, Jardine AG, Mark PB, Cunningham AF, Steedman T, Powell JR, McQuarrie EP, Stevens KK, Dargie HJ, Jardine AG. Association of left atrial volume with mortality among ESRD patients with left ventricular hypertrophy referred for kidney transplantation. Am J Kidney Dis. 2010;55(6):1088–96.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003;63(4):1483–90.CrossRefPubMedGoogle Scholar
  34. 34.
    Ong LM, Narayanan P, Goh HK, Manocha AB, Ghazali A, Omar M, Mohamad S, Goh BL, Shah S, Seman MR, Vaithilingam I, Ghazalli R, Rahmat K, Shaariah W, Ching CH, Oral Paricalcitol in ESRD Study Group. Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism. Nephrology (Carlton). 2013;18(3):194–200.CrossRefGoogle Scholar
  35. 35.
    Fishbane S, Shapiro WB, Corry DB, Vicks SL, Roppolo M, Rappaport K, Ling X, Goodman WG, Turner S, Charytan C. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol. 2008;3(6):1718–25.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Ketteler M, Martin KJ, Cozzolino M, Goldsmith D, Sharma A, Khan S, Dumas E, Amdahl M, Marx S, Audhya P. Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study. Nephrol Dial Transplant. 2012;27(5):1942–9.CrossRefPubMedGoogle Scholar
  37. 37.
    Ketteler M, Martin KJ, Wolf M, Amdahl M, Cozzolino M, Goldsmith D, Sharma A, Marx S, Khan S. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrol Dial Transplant. 2012;27(8):3270–8.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Cozzolino M, Ketteler M, Martin KJ, Sharma A, Goldsmith D, Khan S. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study. Nephrol Dial Transplant. 2014;29(4):899–905.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Renal and Dialysis UnitSan Paulo HospitalMilanItaly
  2. 2.Renal Division, Department of Health Sciences, San Paolo HospitalUniversity of MilanMilanItaly

Personalised recommendations